Stock GLMD GALMED PHARMACEUTICALS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Galmed Pharmaceuticals Ltd.

Equities

GLMD

IL0011313900

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 03:51:37 2024-04-19 pm EDT 		5-day change 1st Jan Change
0.37 USD -2.30% Intraday chart for Galmed Pharmaceuticals Ltd. -11.26% -18.29%
Apr. 04 Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 15 Galmed Pharmaceuticals Ltd. Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of Nash and Liver Fibrosis CI

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Galmed Pharmaceuticals Ltd. Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of Nash and Liver Fibrosis CI
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Sector Update: Health Care Stocks Higher Late Tuesday Afternoon MT
Sector Update: Health Care MT
Top Midday Decliners MT
Galmed Pharmaceuticals Expects Minimum Six Months Delay in Primary Sclerosing Cholangitis Study MT
Galmed Pharmaceuticals Ltd. Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis CI
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Maxim Upgrades Galmed Pharmaceuticals to Buy From Hold, Price Target is $4 MT
Top Midday Decliners MT
Galmed Pharmaceuticals Prices $7 Million Securities Offering; Shares Slump MT
Top Premarket Decliners MT
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Galmed Pharmaceuticals Ltd. Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis CI
Wall Street Set to Open Higher; April Jobs Report Tops Expectations MT
Top Premarket Gainers MT
Galmed Pharmaceuticals Forms a Strategic Partnership with OnKai CI
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Galmed Pharmaceuticals Receives US Patent for Aramchol Meglumine Salt MT
Galmed Pharmaceuticals Ltd. Announces Issuance of New Composition of Matter Patent for Aramchol Meglumine Salt CI
OnKai Inc. announced that it expects to receive $2.5 million in funding from Galmed Pharmaceuticals Ltd. and other investors CI
Galmed Pharmaceuticals Says Open-label Part of Phase 3 Aramchol Shows Fibrosis Improvement in Nonalcoholic Steatohepatitis Patients MT
Galmed Pharmaceuticals Ltd. Reports Results from the Open-Label Part of the Armor Study Showing Improvements in Histology, Imaging, and Biomarkers with Aramchol CI
Galmed Pharmaceuticals Gets Extension to Regain Compliance With Nasdaq's Bid Price Requirement MT

Chart Galmed Pharmaceuticals Ltd.

Chart Galmed Pharmaceuticals Ltd.
More charts

Company Profile

Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
Sector
Biotechnology & Medical Research
Calendar
2024-05-07 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.3787 USD
Average target price
1 USD
Spread / Average Target
+164.06%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
GALMED PHARMACEUTICALS LTD. Stock Galmed Pharmaceuticals Ltd.
-18.29% 2.28M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.19% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.81% 96.07B
ARGENX SE Stock argenx SE
-1.80% 21.66B
BIONTECH SE Stock BioNTech SE
-17.66% 20.77B
GENMAB A/S Stock Genmab A/S
-6.91% 18.53B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.00% 16.91B
BEIGENE, LTD. Stock BeiGene, Ltd.
-27.94% 13.79B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
-0.46% 13.33B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+20.24% 10.94B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. GLMD Stock
  4. News Galmed Pharmaceuticals Ltd.
  5. Galmed Pharmaceuticals : Secures FDA OK to Use Aramchol Meglumine in Phase 3 Armor Trial